Coadministration of the DGAT2 inhibitor PF-06865571 with the ACC inhibitor PF-05221304 reduced LFC and largely eliminated hypertriglyceridemia in a 6-week clinical trial follow-up period (NCT03776175 and NCT04321031) [93]. Here, DGAT2 is linked to hypertriglyceridemia.